Safety and Efficacy of NK510 to Treat Gastric Cancer
Status:
Enrolling by invitation
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and
refractory advanced gastric cancer.NK510 will be administered in combination with PD-1
blockade or monoclonal anti-HER2 antibody. Patients are required to undergo a biopsy for
confirmation of tumor PD-L1 and HER2 expression and. The safety and efficacy of this
treatment will be evaluated.